Trademark applications and grants for Savvides, Savvas. Savvides, Savvas has 1 trademark applications. The latest application filed is for "RISKEASE"
Entity Type | INDIVIDUAL |
Address | 5 Pelopos Street Engomi Nicosia 2412 CYPRUS |
Patent Application | Date |
---|---|
CONFIDENTIAL COMPUTING WORKFLOWS 20220277107 - 17/189075 Beekman; Jethro Gideon ;   et al. | 2022-09-01 |
GALECTIN-10 ANTIBODIES 20210332140 - 17/194950 PERCIER; Jean-Michel ;   et al. | 2021-10-28 |
GALECTIN-10 ANTIBODIES 20190367619 - 16/382997 PERCIER; Jean-Michel ;   et al. | 2019-12-05 |
NOVEL TSLP INHIBITORS 20190127440 - 16/091331 Savvides; Savvas ;   et al. | 2019-05-02 |
CRYSTAL STRUCTURE OF FLT3 LIGAND-RECEPTOR COMPLEX 20130288373 - 13/996118 Verstraete; Kenneth ;   et al. | 2013-10-31 |
Galectin-10 antibodies 11,066,473 - 16/382,997 Percier , et al. July 20, 2 | 2021-07-20 |
TSLP inhibitors 11,001,624 - 16/091,331 Savvides , et al. May 11, 2 | 2021-05-11 |
Mark Image Registration | Serial | Trademark Application Date |
---|---|
"RISKEASE" 2626336 76195355 |
RISKEASE 2001-01-17 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.